Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Shinichi Egawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1115-4932; OpenAlex author ID A5005297664, A5137824134. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
128
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 7 papers · 2014: 3 papers · 2015: none · 2016: 3 papers · 2017: 5 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 30

  1. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  2. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  3. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  4. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  5. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  6. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  7. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  8. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  9. MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Ste… Co-author DOI 10.1097/mpa.0000000000000778↗
  10. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  11. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  12. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
  13. Telomerase activity in pancreatic juice differentiates pancreatic cancer from chronic pancreatitis: A meta-analysis. Co-author DOI 10.1016/j.pan.2016.01.007↗
  14. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  15. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  16. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  17. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  18. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded t… Co-author DOI 10.1002/ijc.27797↗
  19. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. Co-author DOI 10.1002/jcp.24280↗
  20. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2013.10.010↗
  21. The expression of S100A4 in human pancreatic cancer is associated with invasion. First author DOI 10.1097/mpa.0b013e31828804e7↗
  22. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  23. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutiona… Co-author DOI 10.1245/s10434-013-3129-9↗
  24. [A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer]. Co-author PMID 24393949↗
  25. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metab… Co-author DOI 10.1007/s11095-012-0728-2↗
  26. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Co-author DOI 10.1097/mpa.0b013e318258055c↗
  27. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Co-author DOI 10.1007/s10147-011-0220-8↗
  28. Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. First author DOI 10.1007/s12328-011-0257-2↗
  29. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activ… Co-author DOI 10.1016/j.bbrc.2011.06.121↗
  30. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based… Co-author DOI 10.1245/s10434-010-1311-x↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 23 shared papers, 2011–2026 · strength 1.67
  2. Sohei Satoi · 7 shared papers, 2014–2026 · strength 1.05
  3. Takao Itoi · 7 shared papers, 2014–2026 · strength 1.04
  4. Masamichi Mizuma · 9 shared papers, 2013–2026 · strength 1.00
  5. Yoshifumi Takeyama · 4 shared papers, 2025–2026 · strength 0.90
  6. Shin Hamada · 6 shared papers, 2013–2026 · strength 0.86
  7. Atsushi Masamune · 6 shared papers, 2013–2026 · strength 0.86
  8. Kohei Nakata · 3 shared papers, 2026 · strength 0.71
  9. Ichiro Yasuda · 3 shared papers, 2026 · strength 0.71
  10. Ken Shirabe · 3 shared papers, 2026 · strength 0.71
  11. Fuyuhiko Motoi · 16 shared papers, 2011–2017 · strength 0.59
  12. Kazuichi Okazaki · 3 shared papers, 2019–2026 · strength 0.54
  13. Manabu Kawai · 3 shared papers, 2014–2026 · strength 0.50
  14. Yuzo Kodama · 2 shared papers, 2026 · strength 0.48
  15. Takashi Hatori · 6 shared papers, 2012–2025 · strength 0.38
  16. Masaji Tani · 4 shared papers, 2014–2025 · strength 0.34
  17. Tooru Shimosegawa · 4 shared papers, 2013–2026 · strength 0.34
  18. Yu Katayose · 9 shared papers, 2011–2017 · strength 0.33
  19. Tsutomu Fujii · 3 shared papers, 2016–2025 · strength 0.31
  20. Masao Tanaka · 6 shared papers, 2012–2017 · strength 0.26
  21. So Yamaki · 1 shared paper, 2026 · strength 0.24
  22. Daisuke Hashimoto · 1 shared paper, 2026 · strength 0.24
  23. Kazumasa Nagai · 1 shared paper, 2026 · strength 0.24
  24. Kei Nakagawa · 5 shared papers, 2013–2017 · strength 0.21
  25. Takanori Morikawa · 5 shared papers, 2011–2017 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.